Skip to content
Multidisciplinary Association for Psychedelic Studies – MAPS

Multidisciplinary Association for Psychedelic Studies - MAPS

  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Policy & Advocacy
    • Health Equity
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in Trial
    • Volunteer
    • Events
    • Resources
  • Store
    • Learning
    • Apparel
    • Accessories
    • Bookshop
    • 7 Principles
Login
  • Donate
0

Featured

TODAY Show: New Research Shows How Psychedelic Drug Can Help People With PTSD

MAPS is on The TODAY Show! This morning, NBC educated millions of people about psychedelic science by airing an interview with MAPS Founder Rick Doblin, Ph.D., and MDMA-assisted therapy study participants …
November 5, 2021

ABC: How MDMA-Assisted Therapy Could Treat PTSD in Ways Current Therapy Can’t

Summary: In an article featuring the perspective of MAPS Founder and Executive Director Rick Doblin, Ph.D., ABC News covers MAPS’ efforts to make MDMA-assisted therapy for PTSD a legal prescription …
May 13, 2021

BBC News: MDMA Could Help Trauma Survivors Face Painful Memories

Summary: BBC News provides their international audience with an in-depth overview of Nature Medicine’s publication of peer-reviewed results from the MAPS-sponsored Phase 3 clinical trial of MDMA-assisted …
May 13, 2021

Scientific American: MDMA Shows New Promise for Trauma, but the Drug Alone Is Not a Cure

Summary: Scientific American explores how the future of mental healthcare may be impacted by MAPS’ first Phase 3 trial of MDMA-assisted therapy for PTSD, the results of which were published one week …
May 12, 2021

Barron’s: The First Phase 3 Success for Psychedelics Will Pave the Way for an Industry

Summary: Author Bill Alpert of Barron’s contrasts MAPS’ leading non-profit and public benefit models with the profit-oriented approach of new psychedelic companies. “None of the for-profits …
May 11, 2021

Newsweek: Molly, Psychedelic Drug, Shows Great Promise As Mental Health Treatment, New Study Finds

Summary: “What the MDMA clearly did, is it allowed people to go into dark places where ordinarily they did not want to go,” says Bessel van der Kolk, M.D., a Principal Investigator of MAPS’ …
May 10, 2021

The New York Times: The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.

Summary: MAPS is featured in an article on the front page of today’s edition of The New York Times! Reporter Andrew Jacobs profiles MAPS Founder and Executive Director Rick Doblin, Ph.D., and highlights …
May 9, 2021

Psychiatry Advisor: Expert Q&A: MAPS and Psychedelic-Assisted Therapy

Summary: Michael Mithoefer, M.D., and Sara Gael, M.A., of MAPS respond to key questions about MAPS’ pioneering work in the psychedelic field in Psychiatry Advisor’s Expert Q&A. Read the …
May 7, 2021

Media Coverage: MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results

Summary: More than two dozen mainstream media outlets are expanding psychedelic education by highlighting the research results from the first MAPS-sponsored Phase 3 trial of MDMA-assisted therapy for posttraumatic …
May 4, 2021

The New York Times: A Psychedelic Drug Passes Big Test for PTSD Treatment

Summary: “In an important step toward medical approval, MDMA . . . was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy,” says …
May 3, 2021

Stanford Social Innovation Review: The Psychedelic Revolution in Mental Health

Summary: In the Spring 2021 edition of the Stanford Social Innovation Review, journalist Marc Gunther dives into the decades-long history of MAPS, discussing its founding in 1986 by Rick Doblin, Ph.D., …
March 21, 2021

Sarasota Herald-Tribune: Can Psychedelics Save the Planet? New College Alum Rick Doblin’s Mission is to Find Out

Summary: Read the Sarasota Herald-Tribune’s front-page profile of MAPS Founder and Executive Director Rick Doblin, Ph.D., which outlines Doblin’s path that led to his founding of MAPS, as well …
January 12, 2021

Posts navigation

Page 1 … Page 3 Older Posts
Multidisciplinary Association for Psychedelic Studies – MAPS
  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
    • Refunds & Returns
    • FAQs
    • Privacy Policy
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Health Equity
    • Policy & Advocacy
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in a Trial
    • Events
    • Resources

Newsletter Sign Up



  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn
  • Reddit
© 1986 - 2022 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved. Disclaimer | Privacy Policy.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Proudly powered by WordPress. Hosted by Pressable.